# US 2013/0156726 A1 · Endometrial stem cells and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156726 A1
- Document ID: US20130156726A1
- Status: Published application
- Kind: A1
- Application number: 13/525,135
- Filed: 2012-06-15
- Published: 2013-06-20
- Earliest claimed: 2007-05-25
- Assignees: Medistem Laboratories, Inc.
- Inventors: THOMAS E. ICHIM; XIAOLONG MENG; NEIL H. RIORDAN
- Web page: https://patentgrep.com/patent/US20130156726A1

## CPC

- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 38/1891: {Angiogenesic factors; Angiogenin}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- C12N 5/0634: {Cells from the blood or the immune system}
- C12N 5/0682: {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N5/0609)}
- C12N 5/0602: {Vertebrate cells}
- C12N 5/0681: {Cells of the genital tract; Non-germinal cells from gonads}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides pluripotent stem cells and methods for making and using pluripotent stem cells. Pluripotent stem cells, among other things, can differentiate into various cell lineages in vitro, ex vivo and in vivo. Pluripotent stem cells, among other things, can also be used to produce conditioned medium.

## Claims

### Claim 1

A human pluripotent stem cell that expresses a marker selected from CD29, CD41a, CD44, CD90, and CD105, and having an ability to proliferate at a rate of 0.5-1.5 doublings per 24 hours in a growth medium.

### Claim 2 (depends on 1)

The human pluripotent stem cell of claim 1, wherein said cell further expresses a marker selected from NeuN, CD9, CD62, CD59, Actin, GFAP, NSE, Nestin, CD73, SSEA-4, hTERT, Oct-4, and tubulin.

### Claim 3 (depends on 1)

The human pluripotent stem cell of claim 1, wherein said cell further expresses a marker selected from hTERT and Oct-4, but does not express a STRO-1 marker, and has an ability to undergo cell division in less than 24 hours in a growth medium.

### Claim 4 (depends on 1)

The human pluripotent stem cell of claim 1, wherein said cell further expresses a STRO-1 marker, and has an ability to proliferate at a rate of 0.5-0.9 doublings per 24 hours in a growth medium.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The human pluripotent stem cell of claim 1, wherein said cell produces matrix metalloprotease 3 (MMP3), matrix metalloprotease 10 (MMP10), GM-CSF, PDGF-BB or angiogenic factor ANG-2.

### Claim 7 (depends on 1)

The human pluripotent stem cell of claim 1, wherein said cell is derived or originates from endometrium, endometrial stroma, endometrial membrane, or menstrual blood.

### Claim at position 8

-18. (canceled)

### Claim 19 (depends on 1)

The human pluripotent stem cell of claim 1, wherein said cell is capable of differentiating into an adipogenic, endothelial, hepatic, osteogenic, neural, pancreatic or myocytic cell lineage.

### Claim 20 (depends on 1)

The human pluripotent stem cell of claim 1, wherein said cell has a stable karyotype for at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or more cell divisions.

### Claim at position 11

-23. (canceled)

### Claim 24 (depends on 1)

The cell population of claim 1, wherein said cell is capable of stimulating, inducing, increasing, promoting, enhancing or augmenting a reparative process in a host.

### Claim 25 (depends on 1)

The human pluripotent stem cell of claim 1, wherein said cell is capable of suppressing, inhibiting, reducing, decreasing, preventing, blocking, limiting or controlling a T cell mediated response in vitro or in vivo.

### Claim at position 14

-27. (canceled)

### Claim 28 (depends on 1)

The human pluripotent stem cell of claim 1, wherein said mesenchymal cell marker is one or more of: CD54, CD106, an HLA-I marker, vimentin, ASMA, collagen-1, or fibronectin, but not a HLA-DR, CD1 17, or a hemopoietic cell marker.

### Claim at position 16

-42. (canceled)

### Claim 43 (depends on 1)

The human pluripotent stem cell of claim 1 wherein said cell or cells is capable of stimulating angiogenesis, inhibiting fibrosis or scar tissue formation, inhibiting inflammation, inhibiting undesired or pathological apoptosis.

### Claim 44 (depends on 1)

The human pluripotent stem cell of claim 1 wherein said cell or cells is capable of stimulating endogenous progenitor cell proliferation, stimulation of endogenous stem cell proliferation, stimulation of endogenous progenitor cell differentiation, stimulation of endogenous stem cell differentiation, stimulation of exogenous progenitor cell proliferation, stimulation of exogenous stem cell proliferation, stimulation of exogenous progenitor cell differentiation, stimulation of exogenous stem cell differentiation.

### Claim at position 19

-56. (canceled)

### Claim 57 (depends on 1)

A medium incubated with the cell population of claim 1 for a period of about 1-72 hours, 3-7 days, or more.

### Claim 58 (depends on 57)

The medium of claim 57, wherein the medium comprises a matrix metalloprotease 3 (MMP3), matrix metalloprotease 10 (MMP10), GM-CSF, PDGF-BB or angiogenic factor ANG-2.

### Claim 59 (depends on 57)

The medium of claim 57, wherein said medium stimulates, increases, induces, enhances or augments cell survival, viability, growth, proliferation or differentiation of a totipotent stem cell, a pluripotent stem cell, a multipotent stem cell or a differentiated cell.

### Claim 60

(canceled)

### Claim 61 (depends on 1)

A method of producing a conditioned growth medium comprising, contacting a liquid growth medium with the cell population of claim 1 under conditions suitable for viability of said population of cells for a period of about 1-72 hours, 3-7 days or more.

### Claim at position 25

-64. (canceled)

### Claim 65 (depends on 57)

A method of stimulating hematopoiesis comprising administering to a subject the conditioned growth medium of claim 57 in an amount sufficient to stimulate hematopoiesis.

### Claim 66 (depends on 57)

A method of inhibiting inflammation comprising administering to a subject the conditioned growth medium of claim 57 in an amount sufficient to inhibit inflammation.

### Claim 67 (depends on 1)

A method of treating a subject in need of stimulation of angiogenesis, comprising administering the cell population of claim 1 to the subject in an amount sufficient to treat the subject.

### Claim at position 29

-76. (canceled)

### Claim 77 (depends on 1)

A method of treating a subject in need of osteocytes or an osteocyte function comprising administering the cell population of claim 1 to the subject in an amount sufficient to increase osteocyte numbers, stimulate osteocyte formation or increase or stimulate an osteocyte function.

### Claim at position 31

-80. (canceled)

### Claim 81 (depends on 1)

A method of treating a subject having or at risk of having a neurological or muscular disease or disorder, comprising administering the cell population of claim 1 to the subject in an amount sufficient to treat the neurological or muscular disease or disorder.

### Claim at position 33

-112. (canceled)

### Claim 113 (depends on 1)

A method of increasing numbers of T regulatory cells in a subject, comprising administering human pluripotent stem cell of claim 1, or the population or plurality of cells of claim 1, to a subject under conditions facilitating increased numbers of T regulatory cells, thereby increasing numbers of T regulatory cells in the subject.

### Claim at position 35

-127. (canceled)

### Claim 128 (depends on 1)

A method of stimulating, increasing, inducing, augmenting, or enhancing immunological tolerance or treating an autoimmune disorder comprising administering the cell population of claim 1 to the subject in an amount sufficient to stimulate, increase, induce, augment, or enhance immunological tolerance or treat the autoimmune disorder.

### Claim 129

(canceled)

### Claim 130 (depends on 1)

A method of stimulating, increasing, inducing, augmenting, or enhancing hematopoiesis comprising administering the cell population of claim 1 to the subject in an amount sufficient to stimulate, increase, induce, augment or enhance hematopoiesis.

### Claim 131 (depends on 1)

A method of stimulating, increasing, inducing, augmenting, or enhancing Angiogenesis comprising administering the cell population of claim 1 to the subject in an amount sufficient to stimulate, increase, induce, augment or enhance angiogenesis.